In December 2021, The Drugs Controller General of India (DCGI) has granted Sun Pharma's wholly owned
subsidiary Emergency Use Authorization (EUA) to manufacture and distribute Molxvir.
In September 2021, with the launch of Revital NXT, Sun Pharma Consumer Healthcare, a division of Sun
Pharmaceutical Industries Ltd., announced its entry into the nutrition bar category in India.
Revital NXT, is a brand extension of Revital H, a health supplement.
In June 2021, Sun Pharmaceuticals acquired the patent license for Dapagliflozin from AstraZeneca. The
company will distribute and promote the drug under the brand name ‘Oxra’.
In May 2021, the company entered a royalty-free, non-exclusive licensing agreement with Eli Lilly and
Company to expand access to the COVID-19 drug, Baricitinib. The company will manufacture and
distribute the drug in India.
March 2021, Sun Pharmaceuticals acquired a 12.5% stake in Australia-based WRS Bioproducts for US$
In February 2021, the company launched a website for its long-term care portfolio in the US,
highlighting the efficacy and safety profile for each product.
In February 2021, it introduced Brivaracetam, an anti-epileptic drug, in multiple dosage forms, a day
after the patent expiry. This drug was developed by UCB, a Belgian-based firm.